Low-dose Gout Drug, Colchicine, Has Been Approved to Reduce Cardiovascular Events in Patients with Coronary Disease

Pendopharm, a division of Pharmascience Inc., has announced an existing anti-inflammatory gout drug as a new repurposed treatment. In August 2021, Health Canada issued a Notice of Compliance (NOC) approving Myinfla ER (colchicine 0.5 mg extended-release tablets), a prescription medication… Continue Reading…